Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    UCB, MRC Collaborate to Advance Antibody Discovery Platform

    By Global Biodefense StaffApril 7, 2015
    3D Model Monoclonal Antibodies (NIH)
    3D Model Monoclonal Antibodies. Credit: Kovac/NIH
    Share
    Facebook LinkedIn Reddit Email

    3D Model Monoclonal Antibodies. Credit: Kovac/NIH

    The United Kingdom’s Medical Research Council (MRC) and global pharmaceutical company UCB have launched a collaboration that will provide scientists with access to cutting-edge technologies to discover new monoclonal antibodies.

    These antibodies will enable scientists to research the mechanisms of human disease, identify novel therapeutic opportunities, and may provide the initial starting points for new treatments.

    Under the joint initiative, MRC funded academic scientists will work in collaboration with UCB scientists to access and apply the company’s novel high-throughput antibody screening capabilities in support of research directed to biological targets which are implicated in human diseases.

    MRC funded scientists will be able to efficiently sample the immune repertoire, potentially assessing over a billion antibody-producing B-cells, to find those rare cells generating antibody with the exact functional properties required to inhibit the relevant disease process.

    “This exciting new partnership with UCB will bring together some of the best UK scientists with UK-based industry to drive forward the quest to discover new treatments,” said Dr Chris Watkins, Director of Translational Research and Industry at the MRC. “Through access to cutting edge technologies such as these, the UK research community can build on its strengths to accelerate research that will bring benefit to patients.”

    It’s anticipated that this joint initiative will initially run for a period of three years, with up to five projects per year being selected for support by UCB and the MRC. UK-based academics will be able to submit research proposals to the MRC later this year and these will be independently assessed to select the best proposals.

    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUSAID Taps Cornell to Advance Ebola Protective Garments
    Next Article Webinar: Strategies for Community Emergency Response Teams

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy